Vicente Anido, Jr., Ph.D. has served as our Chief Executive Officer since July 2013 and as Chairman of our Board since April 2013. Dr. Anido is the former President, Chief Executive Officer, and Director of ISTA Pharmaceuticals, Inc., which was acquired by Bausch + Lomb, Inc. in 2012. Prior to joining ISTA Pharmaceuticals, Dr. Anido served as general partner of Windamere Venture Partners from 2000 to 2001. From 1996 to 1999, Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a drug discovery company. From 1993 to 1996, Dr. Anido served as President of the Americas Region of Allergan, Inc., where he was responsible for Allergan’s commercial operations for North and South America. Prior to joining Allergan, Dr. Anido spent 17 years at Marion Laboratories and Marion Merrell Dow, Inc., including as Vice President, Business Management of Marion’s U.S. Prescription Products Division. Dr. Anido previously served as a member of the board of directors of QLT Inc. from 2012 to 2013, Depomed, Inc. from February 2013 to May 2016, and Nicox S.A. from June 2013 to June 2014. In addition, from 2002 to 2008, Dr. Anido served as a member of the board of directors of Apria Healthcare, Inc. Dr. Anido received his B.S. and M.S. from West Virginia University and his Ph.D. from the University of Missouri, Kansas City.

David A. Hollander, MD, MBA joined Aerie Pharmaceuticals in November 2019 as Chief Research and Development Officer, where he directs preclinical and clinical research, clinical development as well as medical and professional affairs. Dr. Hollander received his B.S. in chemistry with honors and distinction from Stanford University, and earned his medical degree at the University of Pennsylvania School of Medicine. He obtained an M.B.A. in Health Care Management from the Wharton School at the University of Pennsylvania. Dr. Hollander completed his residency in ophthalmology at the University of California, San Francisco, and a Heed Fellowship in Cornea, External Disease and Refractive Surgery at the Jules Stein Eye Institute/University of California, Los Angeles.

Upon completing his fellowship, Dr. Hollander joined the faculty of the Cornea and Uveitis Division at Jules Stein and served as the Assistant Chief of Ophthalmology at the Greater Los Angeles Veterans Affairs Medical Center. Dr. Hollander began his career in industry in 2006 at Allergan as a Medical Director of Ophthalmology. Over the next decade at Allergan, Dr. Hollander held a number of leadership roles including Vice President of Eye Care for US Medical Affairs, VP and Head of Eye Care for Global Medical Affairs, as well as Therapeutic Area Head in Clinical Development for Anterior Segment and Consumer Eye Care. During this time, Dr. Hollander continued to see patients and instruct residents and fellows in cataract surgery and corneal transplantation. In 2010, the residents at the Jules Stein Eye Institute awarded him with the faculty teaching award.

In 2016, Dr. Hollander joined Ora, Inc, the leading ophthalmic CRO, as Chief Medical Officer. While at Ora, Dr. Hollander oversaw medical operations across pharmaceutical and device clinical development, preclinical studies, as well as research and development into new regulatory endpoints, most notably the development of novel mobility courses for evaluating treatments for inherited retinal diseases.

Dr. Hollander has authored more than 75 papers in the peer-reviewed literature and multiple books chapters and holds multiple patents. He is also a reviewer for numerous journals focusing on ophthalmology, current eye research, and managed care. He has lectured nationally and internationally on topics ranging from endpoint selection, genetics, ocular surface disease, innovative treatments in eye care, and collaborations between academic universities and industry.

Casey C. Kopczynski, Ph.D. has served as our Chief Scientific Officer since co-founding our company in 2005. From 2002 to 2005, he was the Managing Partner at Biotech Initiative, LLC, a consulting practice dedicated to emerging biotech companies. He was also previously the Vice President of Research at Ercole Biotech, Inc. from 2003 to 2004, a company developing drugs for the treatment of cancer, inflammation, and orphan genetic diseases. Prior to Ercole Biotech, Inc., Dr. Kopczynski was Director of Research and a founding member of the scientific staff at Exelixis, Inc. from 1996 to 2002. Dr. Kopczynski received his Ph.D. in Molecular, Cellular, and Developmental Biology from Indiana University and was a Jane Coffin Childs Research Fellow at the University of California, Berkeley.

John W. LaRocca, Esq. joined Aerie as our General Counsel in February of 2018. From March 2015 through January 2018, Mr. LaRocca served as Executive Vice President and General Counsel for Eagle Pharmaceuticals, Inc. From December 2005 through December 2012, Mr. LaRocca was Chief Legal Officer for the Americas for Actavis Inc. and from January 2013 through December 2014, he was Deputy General Counsel for Actavis plc. Prior to that, Mr. LaRocca served as Divisional Counsel-US Generics for both Purepac Pharmaceuticals and Alpharma Pharmaceuticals from September 2000 through December 2005. Previously Mr. LaRocca practiced corporate and commercial law in New York with Parker Duryee Rosoff & Haft; Christie & Viener; and Webster & Sheffield. Mr. LaRocca received his B.A. from Columbia College and his J.D. from Columbia Law School.

Kathleen McGinley is our Chief Human Resources Officer and Vice President, Corporate Services. She advised the company as a consultant beginning in 2013 and joined Aerie in 2015 as Vice President, Human Resources and Corporate Services. From July 2012 to August 2013, Ms. McGinley was a partner in TracksGlobal HR Consulting, and from January 2003 to July 2012, Ms. McGinley served as Vice President, Human Resources and Corporate Services for ISTA Pharmaceuticals. Previously, Ms. McGinley served as Vice President, Human Resources for Littlefeet, Inc and Director, Human Resources for CombiChem. Ms. McGinley received her B.S. and M.S. in English Education from the University of Tennessee and is a certified Mediator. She has been on the Biotech Educational Development Board in San Diego and the Board of San Diego Easter Seals.

Thomas A. Mitro has served as our President and Chief Operating Officer since August 2013. From November 2012 to August 2013, Mr. Mitro served as Vice President, Sales and Marketing at Omeros Corporation, a clinical-stage biopharmaceutical company. Prior to this, Mr. Mitro was Vice President, Sales and Marketing at ISTA Pharmaceuticals from July 2002 to July 2012, where he was instrumental in building ISTA’s commercial operations and launching several eye-care products, including Bromday (bromfenac ophthalmic solution) 0.09% and Bepreve (bepotastine besilate ophthalmic solution) 1.5%. Previously, Mr. Mitro held various positions at Allergan, Inc., including Vice President, Skin Care; Vice President, Business Development; and Vice President, e-Business. Mr. Mitro received his B.S. from Miami University.